|
|
Cardiovascular Exchange Summit 2011
|
|
|
|
Major clinical outcome trials of RAAS manipulation
|
|
|
|
Where are we now?
|
|
|
|
Angiotensin-receptor blockade and risk of cancer
|
|
|
|
ARB and cancer occurrence
|
|
|
|
ARB and cancer deaths
|
|
|
|
Antihypertensive drugs and risk of cancer
|
|
|
|
Network meta-analyses
|
|
|
|
ARBs and cancer risk
|
|
|
|
Use of Angiotensin Receptor Blockers and the Risk of Cancer
|
|
|
|
EMA opinion ARBs
|
|
|
|
Where are we now?
|
|
|
|
Elevated plasma renin activity is associated with increased risk of MI
|
|
|
|
VAL-HeFT trial
|
|
|
|
Prognostic value of renin
|
|
|
|
Prorenin and Heart Failure
|
|
|
|
|
|
Cardiospecific overexpression of (P)RR
|
|
|
|
Isoprenalin
|
|
|
|
Prorenin, Renin, and Their Receptor
|
|
|
|
Renin- and prorenin-induced effects
|
|
|
|
(Pro)Renin receptor
|
|
|
|
Where are we now?
|
|
|
|
Aliskiren
|
|
|
|
ASPIRE
|
|
|
|
ASPIRE
|
|
|
|
ASPIRE
|
|
|
|
ASPIRE
|
|
|
|
Progression of left ventricular dysfunction
|
|
|
|
SAVE—Results of the Survival and Ventricular Enlargement Trial
|
|
|
|
All-Cause Mortality
|
|
|
|
Effect of captopril
|
|
|
|
The SAVE Study
|
|
|
|
Meta-analysis of Remodeling Trials
|
|
|
|
Absence of CHF in patients after AMI
|
|
|
|
Ventricular dilatation and infarct size
|
|
|
|
ASPIRE
|
|
|
|
Conclusions
|
|
Deel deze pagina met collega's en vrienden: